CU
CUPR.US Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
- Market cap
- USD 12.9M
- P/E
- -
- P/B
- 3.06x
- ROE
- -212.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is CUPR.US undervalued?
Graham numberThe Graham number of Cuprina Holdings (Cayman) Limited Class A Ordinary Shares cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares fundamental analysis
No fundamental analysis for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares yet.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collage…
Full company profileCuprina Holdings (Cayman) Limited Class A Ordinary Shares financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares annual financial statements (SGD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 58.5K | 56.6K | 101K | 48.3K | 49.9K | 107K |
| Gross Profit | 23.1K | 20.0K | 36.6K | -3.02K | -645.00 | -66.0K |
| Operating Income | -553K | -1.18M | -1.07M | -1.65M | -4.57M | -11.3M |
| EBITDA | -489K | -1.06M | -994K | -1.43M | -4.56M | -11.2M |
| Net Income | -520K | -1.09M | -1.12M | -1.56M | -4.67M | -10.8M |
| EPS | -0.20 | -0.43 | -0.41 | -0.57 | -1.83 | -4.01 |
| Balance Sheet | ||||||
| Total Assets | 953K | 1.44M | 1.59M | 1.75M | 8.50M | 8.50M |
| Total Liabilities | 1.64M | 3.21M | 4.48M | 6.20M | 3.45M | 3.45M |
| Shareholders' Equity | -684K | -1.78M | -2.90M | -4.46M | 5.06M | 5.06M |
| Cash & Short-term Investments | 767K | 565K | 35.3K | 116K | 3.12M | 3.12M |
| Total Debt | 170K | 184K | 122K | 255K | 483K | 483K |
| Cash Flow | ||||||
| Operating Cash Flow | -222K | -1.85M | -1.54M | -1.24M | -9.13M | -14.9M |
| Capital Expenditure | 2.86K | 16.0K | 68.0K | 21.9K | 58.2K | 214K |
| Free Cash Flow | -225K | -1.87M | -1.61M | -1.26M | -9.19M | -15.1M |
| Ratios | ||||||
| ROE | - | - | - | - | -92.4% | -212.8% |
| ROA | -54.5% | -76.2% | -70.6% | -89.4% | -55.0% | -126.5% |
| Net Profit Margin | -888.3% | -1,933.8% | -1,111.0% | -3,229.5% | -9,366.8% | -10,039.2% |
| Debt to Equity | - | - | - | - | 0.10x | 0.10x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares dividends
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares has not paid dividends in the last 5 fiscal years.
Last stock split: 1:8 on May 27, 2026.
Who owns Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
- Insiders 0.00%
- Institutions 1.29%
- Public & others 98.72%
- Shares outstanding 5.89M
- Free float 2.01M
Top funds holding CUPR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 201.00 | 0.01% | 0.00% | May 2026 |
Top institutions holding CUPR.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Caitong International Asset Management Co., Limited. | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Prospect Financial Group LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares company profile
- Company name
- Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
- Ticker
- CUPR.US
- ISIN
- KYG2592E1109
- Exchange
- USA Stocks
- Listed since
- Apr 10, 2025
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10
- Fiscal year end
- December
- Address
- Blk 1090, Singapore, Singapore, 169201
- Phone
- 65 8512 7275
- Website
- cuprina.com.sg
About Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares management
3- Mr. Yong Qi QuekCEO & Director · born 1995
- Mr. Tat Jing ChanChief Financial Officer · born 1993
- Dr. Ronald ShermanMedical & Scientific Director